• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Xylocaine Pump Spray 10%
    / Tec-O-Pharm

    Active Ingredient
    Lidocaine 10 mg / 0.1 ml

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    50 ml

    full basket chart


    As with any local anaesthetic, the safety and effectiveness of lidocaine depends on the proper dosage, the correct technique, adequate precautions and readiness for emergencies.
    The following dosage recommendations should be regarded as a guide. The
    clinician’s experience and knowledge of the patient’s physical status are of
    importance in calculating the required dose.
    The degree of absorption from mucous membranes is variable but especially high from the bronchial tree. Application only to areas below the vocal cords may result in excessive plasma concentrations because of less transfer to the intestine and less first-pass loss.
    Each actuation of the metered-dose valve delivers 10mg Lidocaine base. It is
    unnecessary to dry the site prior to application.
    Xylocaine Pump Spray 10% should not be used on cuffs of endotracheal tubes
    (ETT) made of plastic.
    Otorhinolaryngology: 3 metered doses for puncture of the maxillary sinus or
    other minor surgical procedures.
    Obstetrics – During delivery: Up to 20 metered doses (200mg lidocaine base).
    Introduction of instruments, tubes and catheters into the respiratory and
    digestive tract: Up to 20 metered doses (200mg lidocaine base) for procedures in pharynx, larynx and trachea. During prolonged procedures up to 400 mg of lidocaine may be administered. In addition, when combined with other lidocaine products, the total dose should not exceed 400 mg.
    With application mainly to the larynx, trachea and bronchi, the dose should
    not exceed 20 metered doses (200 mg lidocaine base).
    Dental practice: 1-5 metered doses to the mucous membranes.
    Debilitated or elderly patients, children over 12 years of age, acutely ill patients or patients with sepsis should be given doses commensurate with their age, weight and physical condition.
    In children less than 12 years of age the dose should not exceed 3 mg/kg (e.g. 6
    metered doses in an infant weighing 20 kg). When used mainly in the larynx and
    trachea the dose should be reduced to 1.5 mg/kg. In children less than 3 years of age less concentrated lidocaine solutions are recommended.


    Surface anaesthesia in dental practice for otorhinolaryngology, obstetric and
    Otorhinolaryngology: Puncture of the maxillary sinus and minor surgical procedures in the oral and nasal cavity, pharynx and epipharynx.
    Obstetrics: During the final stages of delivery and before the episiotomy and perineal suturing as supplementary pain control.
    Introduction of instruments, tubes and catheters into the respiratory and digestive tract: Provides surface anaesthesia for the oropharyngeal and tracheal areas to reduce reflex activity, attenuate haemodynamic responses and facilitates insertion of the tube or the passage of instruments during endotracheal intubation and endoscopic procedures of the airways and upper gastrointestinal tract.
    Dental practice: Before injections, dental impressions, X-ray photography, removal of calculus.


    Known history of hypersensitivity to local anaesthetics of the amide type or to
    other components of the spray solution.

    Special Precautions

    See prescribing information for full details.

    Side Effects

    See prescribing information for full details.

    Drug interactions

    Lidocaine should be used with caution in patients receiving other local
    anaesthetics or agents structurally related to amide-type local anaesthetics, e.g. antiarrhythmics such as mexiletin and tocainide, since the toxic effects are
    Specific interaction studies with lidocaine and anti-arrhythmic drugs class III (e.g. amiodarone) have not been performed, but caution is advised.
    Drugs that reduce the clearance of lidocaine (e.g. cimetidine or betablockers) may cause potentially toxic plasma concentrations when lidocaine is given in repeated high doses over a long time period. Such interactions should therefore be of no clinical importance following short-term treatment with lidocaine (e.g. Xylocaine Pump Spray 10%) at recommended doses.

    Pregnancy and Lactation

    Pregnancy: There is no, or inadequate evidence of safety of the drug in human pregnancy, but it has been in wide use for many years without apparent ill consequence and animal studies have shown to hazard. If drug therapy is needed in pregnancy, this drug can be used if there is no safer alternative.
    Lactation: Lidocaine enters the mother’s milk, but in such small quantities that there is generally no risk of the child being affected at therapeutic dose levels.


    See prescribing information for full details.

    AstraZeneca AB Gärtunavägen Sweden